BioSpace News Archive

The Pathway Development Consortium (PDC), a public-private collaboration founded by REGENXBIO Inc. (Nasdaq: RGNX) and Solid Biosciences Inc. (Nasdaq: SLDB), today announced the publication of a peer-reviewed manuscript, Micro-dystrophin expression as a surrogate endpoint for Duchenne muscular dystrophy clinical trials, in Human Gene Therapy.

IceCure Medical Ltd today announced its participation in the Society of Interventional Oncology’s Annual Scientific Meeting (“SIO2023") in Washington, D.C. on January 19 - 23, 2023.

Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, announced the appointment of Angie Swenson as Vice President of Clinical Operations.

Innocoll Holdings Ltd., a global biotech pharmaceutical company and portfolio business of Gurnet Point Capital, announced the appointment of Kimball Hall, a seasoned commercial operations executive, as President and Chief Executive Officer.

Alzamend Neuro, Inc. today announced that it will be presenting virtually at the upcoming Sequire Biotechnology Conference on Thursday, February 2, 2023.

Sesen Bio, Inc. (Nasdaq: SESN) today issued the following statement reiterating the Company’s confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. (Carisma) in response to the release issued yesterday by Bradley Radoff and Michael Torok and their affiliates (collectively, the “Investor Group”).

The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 54 cents per share of common stock.

Twist Bioscience Corporation announced the shipments of the first products from its second manufacturing site, the Factory of the Future, in Wilsonville, Oregon.

Mitsubishi Tanabe Pharma America, Inc. announced that nearly 4,000 people with amyotrophic lateral sclerosis have received RADICAVA ORS® since the therapy became available in the U.S. in June 2022, and 79% of patients who started treatment with RADICAVA ORS or intravenous RADICAVA® between June 1, 2022 and September 30, 2022 have continued treatment for three months or more through December.

One of the nation’s top nephrologists and advanced kidney disease researchers, Rajnish Mehrotra, MD, MS, will receive the National Kidney Foundation’s Dr. J. Michael Lazarus Distinguished Award at the 2023 Spring Clinical Meetings in Austin, TX, April 11-15.